152 related articles for article (PubMed ID: 21763306)
1. Immunohistochemical detection of a specific receptor for lipocalin2 (solute carrier family 22 member 17, SLC22A17) and its prognostic significance in endometrial carcinoma.
Miyamoto T; Asaka R; Suzuki A; Takatsu A; Kashima H; Shiozawa T
Exp Mol Pathol; 2011 Oct; 91(2):563-8. PubMed ID: 21763306
[TBL] [Abstract][Full Text] [Related]
2. Laser-captured microdissection-microarray analysis of the genes involved in endometrial carcinogenesis: stepwise up-regulation of lipocalin2 expression in normal and neoplastic endometria and its functional relevance.
Miyamoto T; Kashima H; Suzuki A; Kikuchi N; Konishi I; Seki N; Shiozawa T
Hum Pathol; 2011 Sep; 42(9):1265-74. PubMed ID: 21334721
[TBL] [Abstract][Full Text] [Related]
3. Lipocalin 2 expression is associated with aggressive features of endometrial cancer.
Mannelqvist M; Stefansson IM; Wik E; Kusonmano K; Raeder MB; Øyan AM; Kalland KH; Moses MA; Salvesen HB; Akslen LA
BMC Cancer; 2012 May; 12():169. PubMed ID: 22559235
[TBL] [Abstract][Full Text] [Related]
4. Lipocalin-2 and matrix metalloproteinase-9 expression in high-grade endometrial cancer and their prognostic value.
Srdelić Mihalj S; Kuzmić-Prusac I; Zekić-Tomaš S; Šamija-Projić I; Čapkun V
Histopathology; 2015 Aug; 67(2):206-15. PubMed ID: 25522256
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and Structural Characterization of the Interaction between the Siderocalin NGAL/LCN2 (Neutrophil Gelatinase-associated Lipocalin/Lipocalin 2) and the N-terminal Domain of Its Endocytic Receptor SLC22A17.
Cabedo Martinez AI; Weinhäupl K; Lee WK; Wolff NA; Storch B; Żerko S; Konrat R; Koźmiński W; Breuker K; Thévenod F; Coudevylle N
J Biol Chem; 2016 Feb; 291(6):2917-30. PubMed ID: 26635366
[TBL] [Abstract][Full Text] [Related]
6. Lipocalin2 enhances the matrix metalloproteinase-9 activity and invasion of extravillous trophoblasts under hypoxia.
Kobara H; Miyamoto T; Suzuki A; Asaka R; Yamada Y; Ishikawa K; Kikuchi N; Ohira S; Shiozawa T
Placenta; 2013 Nov; 34(11):1036-43. PubMed ID: 23972287
[TBL] [Abstract][Full Text] [Related]
7. Inverse Regulation of Lipocalin-2/24p3 Receptor/SLC22A17 and Lipocalin-2 Expression by Tonicity, NFAT5/TonEBP and Arginine Vasopressin in Mouse Cortical Collecting Duct Cells mCCD(cl.1): Implications for Osmotolerance.
Probst S; Scharner B; McErlean R; Lee WK; Thévenod F
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671521
[TBL] [Abstract][Full Text] [Related]
8. Lipocalin 2 Enhances Migration and Resistance against Cisplatin in Endometrial Carcinoma Cells.
Miyamoto T; Kashima H; Yamada Y; Kobara H; Asaka R; Ando H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
PLoS One; 2016; 11(5):e0155220. PubMed ID: 27168162
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of core 2 β1,6-N-acetylglucosaminyl transferase 1 (C2GnT1) in endometrioid-type endometrial carcinoma: a novel potential prognostic factor.
Miyamoto T; Suzuki A; Asaka R; Ishikawa K; Yamada Y; Kobara H; Nakayama J; Shiozawa T
Histopathology; 2013 Jun; 62(7):986-93. PubMed ID: 23617619
[TBL] [Abstract][Full Text] [Related]
10. Lipocalin 2 promotes the migration and invasion of esophageal squamous cell carcinoma cells through a novel positive feedback loop.
Du ZP; Wu BL; Xie YM; Zhang YL; Liao LD; Zhou F; Xie JJ; Zeng FM; Xu XE; Fang WK; Li EM; Xu LY
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2240-50. PubMed ID: 26190820
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
Fakhry H; Miyamoto T; Kashima H; Suzuki A; Ke H; Konishi I; Shiozawa T
Hum Pathol; 2010 Jun; 41(6):848-58. PubMed ID: 20178884
[TBL] [Abstract][Full Text] [Related]
12. Lipocalin 2-mediated growth suppression is evident in human erythroid and monocyte/macrophage lineage cells.
Miharada K; Hiroyama T; Sudo K; Danjo I; Nagasawa T; Nakamura Y
J Cell Physiol; 2008 May; 215(2):526-37. PubMed ID: 18064607
[TBL] [Abstract][Full Text] [Related]
13. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 is significantly associated with stage of tumor and predicts poor survival in endometrial carcinoma patients.
Khabaz MN; Abdelrahman AS; Butt NS; Al-Maghrabi B; Al-Maghrabi J
Ann Diagn Pathol; 2017 Oct; 30():47-51. PubMed ID: 28965628
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma.
Yokoyama Y; Sato S; Futagami M; Fukushi Y; Sakamoto T; Umemoto M; Saito Y
Gynecol Oncol; 2000 Jun; 77(3):413-8. PubMed ID: 10831352
[TBL] [Abstract][Full Text] [Related]
16. Expression of uterine lipocalin 2 and its receptor during early- to mid-pregnancy period in mares.
Haneda S; Nagaoka K; Nambo Y; Kikuchi M; Nakano Y; Li J; Matsui M; Miyake YI; Imakawa K
J Reprod Dev; 2017 Apr; 63(2):127-133. PubMed ID: 27980236
[TBL] [Abstract][Full Text] [Related]
17. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
Yokoyama Y; Charnock-Jones DS; Licence D; Yanaihara A; Hastings JM; Holland CM; Emoto M; Sakamoto A; Sakamoto T; Maruyama H; Sato S; Mizunuma H; Smith SK
Clin Cancer Res; 2003 Apr; 9(4):1361-9. PubMed ID: 12684405
[TBL] [Abstract][Full Text] [Related]
18. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification.
Zhang Y; Fan Y; Mei Z
Cancer Epidemiol; 2012 Oct; 36(5):e294-9. PubMed ID: 22728279
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatic analysis of the
Candido S; Tomasello B; Lavoro A; Falzone L; Gattuso G; Russo A; Paratore S; McCubrey JA; Libra M
Front Cell Dev Biol; 2022; 10():945586. PubMed ID: 36211450
[TBL] [Abstract][Full Text] [Related]
20. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma.
Meng FL; Yin MZ; Song HT; Yang H; Lou G; Zhou RL
Int J Gynecol Cancer; 2010 Jul; 20(5):745-50. PubMed ID: 20966643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
